S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Would Buffett Approve of This Growth Strategy? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Inflation is Why a Soft Landing is Bad for the Economy
Would Buffett Approve of This Growth Strategy? (Ad)
EU announces plans to better protect its sensitive technologies from foreign snooping
A Growing 4% Dividend makes this a REIT to Shop For
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Would Buffett Approve of This Growth Strategy? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Inflation is Why a Soft Landing is Bad for the Economy
Would Buffett Approve of This Growth Strategy? (Ad)
EU announces plans to better protect its sensitive technologies from foreign snooping
A Growing 4% Dividend makes this a REIT to Shop For
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Would Buffett Approve of This Growth Strategy? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Inflation is Why a Soft Landing is Bad for the Economy
Would Buffett Approve of This Growth Strategy? (Ad)
EU announces plans to better protect its sensitive technologies from foreign snooping
A Growing 4% Dividend makes this a REIT to Shop For
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Would Buffett Approve of This Growth Strategy? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Inflation is Why a Soft Landing is Bad for the Economy
Would Buffett Approve of This Growth Strategy? (Ad)
EU announces plans to better protect its sensitive technologies from foreign snooping
A Growing 4% Dividend makes this a REIT to Shop For
NASDAQ:CTSO

Cytosorbents (CTSO) Stock Forecast, Price & News

$1.73
-0.05 (-2.81%)
(As of 10/3/2023 ET)
Compare
Today's Range
$1.72
$1.81
50-Day Range
$1.73
$3.80
52-Week Range
$1.03
$4.59
Volume
42,266 shs
Average Volume
72,925 shs
Market Capitalization
$76.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75

Cytosorbents MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
174.6% Upside
$4.75 Price Target
Short Interest
Bearish
3.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.84mentions of Cytosorbents in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$9,570 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.55) to ($0.11) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

650th out of 966 stocks

Surgical & Medical Instruments Industry

70th out of 95 stocks


CTSO stock logo

About Cytosorbents (NASDAQ:CTSO) Stock

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

CTSO Price History

CTSO Stock News Headlines

CytoSorbents Announces Reappointment Of Kathleen Bloch As Full-time CFO
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
H.C. Wainwright Reaffirms Their Buy Rating on Cytosorbents (CTSO)
CytoSorbents: Q2 Earnings Snapshot
Cytosorbents Appoints Alexander D'Amico New CFO
CTSO - Cytosorbents Corporation
See More Headlines
Receive CTSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter.

CTSO Company Calendar

Last Earnings
8/01/2023
Today
10/03/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTSO
Employees
198
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.75
High Stock Price Forecast
$5.50
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+174.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-32,810,000.00
Pretax Margin
-75.71%

Debt

Sales & Book Value

Annual Sales
$34.69 million
Book Value
$0.81 per share

Miscellaneous

Free Float
40,769,000
Market Cap
$76.74 million
Optionable
Optionable
Beta
0.84
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Phillip P. Chan M.D. (Age 53)
    Ph.D., CEO & Director
    Comp: $541.93k
  • Mr. Vincent J. Capponi M.S. (Age 65)
    MS, Pres & COO
    Comp: $452.62k
  • Ms. Kathleen P. Bloch C.P.A.Ms. Kathleen P. Bloch C.P.A. (Age 68)
    CPA, M.B.A., MBA, Chief Financial Officer
    Comp: $395.43k
  • Dr. Efthymios N. Deliargyris FACC (Age 54)
    FESC, FSCAI, M.D., Chief Medical Officer
    Comp: $463.15k
  • Ms. Terri Anne Powers M.B.A.
    VP of Investor Relations & Corp. Communications
  • Dr. Christian Steiner M.D.
    Exec. VP of Sales & Marketing
  • Mr. Christopher Cramer M.B.A.
    M.S., MBA, MS, Sr. VP of Bus. Devel.
  • Dr. Irina B. Kulinets Ph.D. (Age 68)
    Sr. VP of Global Regulatory Affairs
  • Jodi Hoover
    Exec.
  • Dr. Robert H. Bartlett M.D. (Age 84)
    Co-Chairman of Cardiac Surgery Advisory Board & Consultant













CTSO Stock - Frequently Asked Questions

Should I buy or sell Cytosorbents stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CTSO shares.
View CTSO analyst ratings
or view top-rated stocks.

What is Cytosorbents' stock price forecast for 2023?

2 equities research analysts have issued 12-month price objectives for Cytosorbents' stock. Their CTSO share price forecasts range from $4.00 to $5.50. On average, they predict the company's share price to reach $4.75 in the next twelve months. This suggests a possible upside of 174.6% from the stock's current price.
View analysts price targets for CTSO
or view top-rated stocks among Wall Street analysts.

How have CTSO shares performed in 2023?

Cytosorbents' stock was trading at $1.55 at the beginning of 2023. Since then, CTSO stock has increased by 11.6% and is now trading at $1.73.
View the best growth stocks for 2023 here
.

Are investors shorting Cytosorbents?

Cytosorbents saw a increase in short interest in September. As of September 15th, there was short interest totaling 1,220,000 shares, an increase of 19.6% from the August 31st total of 1,020,000 shares. Based on an average daily volume of 66,000 shares, the days-to-cover ratio is currently 18.5 days. Currently, 3.2% of the company's stock are sold short.
View Cytosorbents' Short Interest
.

When is Cytosorbents' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our CTSO earnings forecast
.

How were Cytosorbents' earnings last quarter?

Cytosorbents Co. (NASDAQ:CTSO) posted its quarterly earnings data on Tuesday, August, 1st. The medical research company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.03. The medical research company earned $9.42 million during the quarter, compared to analyst estimates of $11.03 million. Cytosorbents had a negative net margin of 72.71% and a negative trailing twelve-month return on equity of 82.93%.

What is Phillip Chan's approval rating as Cytosorbents' CEO?

11 employees have rated Cytosorbents Chief Executive Officer Phillip Chan on Glassdoor.com. Phillip Chan has an approval rating of 26% among the company's employees. This puts Phillip Chan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Cytosorbents to a friend.

What other stocks do shareholders of Cytosorbents own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include Rekor Systems (REKR), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), AbbVie (ABBV), Inovio Pharmaceuticals (INO), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

What is Cytosorbents' stock symbol?

Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."

How do I buy shares of Cytosorbents?

Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytosorbents' stock price today?

One share of CTSO stock can currently be purchased for approximately $1.73.

How much money does Cytosorbents make?

Cytosorbents (NASDAQ:CTSO) has a market capitalization of $76.74 million and generates $34.69 million in revenue each year. The medical research company earns $-32,810,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

How many employees does Cytosorbents have?

The company employs 198 workers across the globe.

How can I contact Cytosorbents?

Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The official website for the company is www.cytosorbents.com. The medical research company can be reached via phone at (732) 329-8885, via email at avogel@cytosorbents.com, or via fax at 732-329-8650.

This page (NASDAQ:CTSO) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -